Naureen Quibria
Stock Analyst at Capital One
(0.10)
# 4,076
Out of 4,670 analysts
13
Total ratings
15.38%
Success rate
-42.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $6.44 | +288.20% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $1.93 | +419.48% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.70 | +196.30% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $0.82 | +1,115.81% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $32.28 | +160.22% | 1 | Aug 16, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 2 | Apr 4, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $13.72 | +191.55% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $5.32 | +106.77% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $0.90 | +677.78% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $4.69 | +347.38% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $5.76 | +3,025.00% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $6.44
Upside: +288.20%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.93
Upside: +419.48%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.70
Upside: +196.30%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $0.82
Upside: +1,115.81%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $32.28
Upside: +160.22%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $13.72
Upside: +191.55%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $5.32
Upside: +106.77%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $0.90
Upside: +677.78%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $4.69
Upside: +347.38%
Oct 14, 2021
Initiates: Buy
Price Target: $180
Current: $5.76
Upside: +3,025.00%